Psychiatric medication management for Hollywood — residential-level optimization, 50 minutes away.

For Hollywood clients whose outpatient medication trials have stalled — antidepressants at inadequate doses, augmentation never trialed, adherence uncertain — RECO Immersive runs the pharmacology on a residential cadence: observed dosing, weekly lithium and valproate levels during titration, side-effect resolution at the next round rather than the next month. The Delray Beach campus is 35 miles north up I-95, roughly 50 minutes outside rush hour. Coordination with concurrent Spravato, ketamine, or rTMS at RECO Health runs through a single psychiatry team rather than across independent prescribers.

Hollywood sits 35 miles south of RECO Immersive’s Delray Beach campus — a 50-minute drive up I-95 outside of rush hour, considerably longer at 8 a.m. or between 4 and 6 p.m. That distance functions clinically. For adults whose depression, bipolar disorder, PTSD, or treatment-resistant anxiety has stalled in outpatient psychiatry, admission to residential care in Delray separates the medication trial from the routines — the sleep patterns, the alcohol use, the missed doses, the environmental stressors — that were quietly undermining response at home.

Psychiatric medication management, embedded in residential care

Within RECO Immersive, psychiatry is not a weekly appointment negotiated around groups. It is a continuous clinical presence, with visit-anchored measurement (PHQ-9, GAD-7, YBOCS where indicated, ASRS for co-occurring ADHD), observed adherence, and same-week medication adjustment when response data warrants. That cadence is what the residential level of care is best positioned to deliver, and what most outpatient trials cannot match on speed or precision.

When a Hollywood client arrives having cycled through sertraline, escitalopram, and bupropion without adequate response, the residential setting allows the attending to run a proper augmentation trial — lithium adjunct, aripiprazole at 2 to 5 mg, or a switch to venlafaxine at a therapeutic dose — with daily observation of tolerability rather than a phone call between visits. This is where residential psychiatric medication management adds the most pharmacologic value: optimization the outpatient environment structurally cannot deliver.

What observed adherence and daily monitoring change

In outpatient care, whether the client actually takes the medication as prescribed is a matter of self-report supplemented by pill counts. In residential care, adherence is observed at every scheduled dose by nursing staff. That difference matters most for medications with narrow therapeutic windows — lithium, valproate, lamotrigine during the titration window — where a missed dose changes the level, and where a level drawn on inconsistent adherence is not actually informative.

The difference matters equally for medications where the outpatient trial stopped working because of side effects the client never fully reported. In residential, tolerability issues surface immediately at the next round with the psychiatry team — early sedation on quetiapine, akathisia on aripiprazole, GI intolerance on venlafaxine, sexual side effects on SSRIs — and get addressed within the same week rather than two weeks later, after the client has already discontinued and returned to symptomatic baseline. The regimen the client leaves on is one that has been actively tested against tolerability, not one they said they could tolerate.

Comprehensive lab monitoring during the residential stay

Baseline labs on admission are standard: CBC, CMP, TSH, B12 and folate, vitamin D, lipid panel, HbA1c, urine drug screen, and urine pregnancy where clinically indicated. Where the residential setting adds value is the ongoing monitoring cadence — driven by medication choice and clinical response rather than by outpatient scheduling constraints. Lithium levels are drawn weekly during titration and after any dose change until steady state; valproate levels follow a similar cadence.

For clients started or continued on second-generation antipsychotics — quetiapine, aripiprazole, olanzapine — metabolic panels are checked at admission and repeated at discharge, with weight and fasting glucose monitored throughout the stay. EKG is obtained where QTc-prolonging combinations warrant, particularly when methadone, ondansetron, or higher-dose antipsychotics are on board. Thyroid function is rechecked before discharge for clients on lithium. None of that monitoring is optional — it is the reason residential pharmacology is defensible.

Coordination with concurrent interventional treatment

RECO Immersive clients frequently overlap with the interventional psychiatry programs at RECO Health — Spravato (esketamine) for treatment-resistant depression, IV or IM ketamine protocols, and rTMS delivered at 3000 pulses per session at 120% of motor threshold across the standard 36-session course. The medication management team coordinates directly with the interventional providers rather than negotiating across independent prescribers.

That coordination is concrete: benzodiazepines are tapered before or during rTMS courses because of their attenuating effect on cortical excitability; lamotrigine adjustments are timed against ketamine infusions where glutamatergic overlap is a consideration; oral antidepressant adherence is confirmed daily during the acute Spravato induction phase. When interventional treatment produces a response, the ongoing pharmacology plan is written to consolidate and hold that response, not to compete with it.

Co-occurring substance use — integration with the pharmacology plan

For Hollywood clients presenting with co-occurring substance use disorder, pharmacology is written across two problem lists rather than one. Medical detox, where indicated, is scored using CIWA-Ar for alcohol withdrawal and COWS for opioid withdrawal, with medically supervised tapers preceding the psychiatric optimization phase. Medications for addiction treatment — buprenorphine-naloxone, extended-release naltrexone, acamprosate, or disulfiram — are integrated based on the ASAM Criteria dimensions documented at intake.

Modality-based work runs in parallel: CBT and DBT groups anchor the therapy schedule, EMDR and prolonged exposure address PTSD where trauma is a driver of use, MI is used at the individual level where readiness is uneven, and ACT informs the values work that stabilizes the post-discharge plan. The pharmacology plan reflects that context rather than sitting outside of it.

The medication plan the client leaves with — and admission from Hollywood

Discharge from RECO Immersive includes a documented medication plan the client actually understands. That plan lists the current regimen with the clinical rationale for each agent, next-step contingencies if response attenuates, the monitoring schedule (next lithium level, next metabolic panel, next EKG), and the specific symptoms that warrant an earlier outpatient visit. The plan transfers cleanly to the RECO Health outpatient team when the client is stepping down into PHP or IOP after residential, or to a home-community prescriber closer to Hollywood Beach, Emerald Hills, or Hollywood Lakes.

Admission logistics from Hollywood are handled directly by intake. Most commercial plans — Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS — are verified in-network for residential mental health benefits before admission, with the clinical necessity documentation drawn from the phone assessment. Transport up I-95 is coordinated the same day. The first 72 hours are structured around the psychiatric intake, medication reconciliation against the last outpatient regimen, and baseline labs drawn on the admission day or the following morning — with the initial residential order set written before the first evening dose.

Serving residents of: Hollywood Beach, Emerald Hills, Hollywood Lakes, Hollywood Hills, Oakwood.